Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

Amgen gets approvals for BeiGene deal, Nplate drug

By   /   Monday, December 2nd, 2019  /   Comments Off on Amgen gets approvals for BeiGene deal, Nplate drug

    Print       Email
Amgen received two approvals from regulators over the Thanksgiving weekend, allowing its deal to acquire a minority stake in a Chinese biotechnology firm to move forward and granting orphan drug status to anemia treatment Nplate. The Thousand Oaks-based pharma giant announced the deal to acquire a 20 percent stake in oncology research firm BeiGene for…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email